We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
This web publication constitutes a notice of recommendations for the scheduling of New Chemical Entities for inclusion in the Poisons Standard under section 52D(2)(b) of the Therapeutic Goods Act 1989, whereby a new Poisons Standard (including schedules containing the names or descriptions of substances or classes of substances) is prepared in substitution for the current Poisons Standard. The new Poisons Standard will come into effect on 1 February 2020.
Note
New text is shown as green, larger font, with a horizontal line above it.
1.1. Recommendation in relation to acalabrutinib
Schedule 4 - New Entry
ACALABRUTINIB.
Index - New Entry
ACALABRUTINIB
Schedule 4
Date of effect
1 February 2020
1.2. Recommendation in relation to alanylglutamine
Schedule 4 - New Entry
ALANYLGLUTAMINE.
Index - New Entry
ALANYLGLUTAMINE
Schedule 4
Date of effect
1 February 2020
1.3. Recommendation in relation to baloxavir marboxil
Schedule 4 - New Entry
BALOXAVIR MARBOXIL.
Index - New Entry
BALOXAVIR MARBOXIL
Schedule 4
Date of effect
1 February 2020
1.4. Recommendation in relation to enasidenib
Schedule 4 - New Entry
ENASIDENIB.
Index - New Entry
ENASIDENIB
Schedule 4
Date of effect
1 February 2020
1.5. Recommendation in relation to entrectinib
Schedule 4 - New Entry
ENTRECTINIB.
Index - New Entry
ENTRECTINIB
Schedule 4
Date of effect
1 February 2020
1.6. Recommendation in relation to gilteritinib
Schedule 4 - New Entry
GILTERITINIB.
Index - New Entry
GILTERITINIB
Schedule 4
Date of effect
1 February 2020
1.7. Recommendation in relation to siponimod
Schedule 4 - New Entry
SIPONIMOD.
Index - New Entry
SIPONIMOD
Schedule 4
Date of effect
1 February 2020
1.8. Recommendation in relation to sodium glycerophosphate hydrate
Schedule 4 - New Entry
SODIUM GLYCEROPHOSPHATE HYDRATE.
Index - New Entry
SODIUM GLYCEROPHOSPHATE HYDRATE
Schedule 4
Date of effect
1 February 2020
1.9. Recommendation in relation to upadacitinib
Schedule 4 - New Entry
UPADACITINIB.
Index - New Entry
UPADACITINIB
Schedule 4
Date of effect
1 February 2020
1.10. Recommendation in relation to voretigene neparvovec
Schedule 4 - New Entry
VORETIGENE NEPARVOVEC.
Index - New Entry
VORETIGENE NEPARVOVEC
Schedule 4
Date of effect
1 February 2020